Loading…
← CockpitCompetitor Analysis › TSHA Taysha Gene Therapies, Inc.Open in the cockpit ↗

Taysha Gene Therapies, Inc.TSHACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops AAV gene therapies for rare, monogenic central nervous system diseases in children.

Momentum weak 21
Mkt cap
$1.30B
US dollars, full cap
Free float
84%
of shares outstanding
$/day
$12.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 11.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$3.99
1D-0.2%
1W-6.8%
1M-2.9%
3M-34.7%
6M-27.3%
YTD-27.4%
1Y-3.2%
ATR %6.8%
Beta1.65
52w lowhigh45.3% off high

What Taysha Gene Therapies does

Develops AAV gene therapies for rare, monogenic central nervous system diseases in children.

Has no product on sale, so it funds trials with money raised from investors, and revenue would start only with an approval or a licensing deal. A gene therapy is meant to be a one-time treatment, which is why such drugs are priced per patient rather than as a recurring prescription.

Products and services

  • TSHA-102 (Rett syndrome)
  • TSHA-120 (giant axonal neuropathy)

Customers

  • Pediatric neurologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • CNS gene therapy

What could go right

  • Pivotal trial data readouts
  • Orphan drug pricing and exclusivity potential

What could go wrong

  • Clinical trial failure risk
  • Ongoing cash runway and financing needs

Moat: none (IP / patents). Addresses ultra-rare pediatric CNS diseases with no approved treatments, but is clinical-stage and cash-constrained.

Headquarters: Dallas, Texas, US · Founded: 2018 · Employees: 99

Named competitors

Taysha Gene Therapies at a glance

Size Taysha Gene Therapies (TSHA) is a United States Health Care company (Biotechnology) with a market value of $1.30B, the 2068th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.99 on 18 Nov 2026.

Performance Over six months the shares fell 27.3%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue fell 13.1% over the last twelve months (peer median +15.8%); the operating margin is -2,998.0% (peer median -38.9%).

Valuation It trades at 170.1× enterprise value to sales against a peer median of 8.4× (4th most expensive of 19).

Short interest Short interest is 16.4% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 80TSHA 72
Six months, rebased to 100: Taysha Gene Therapies against the median of its 20 peers (local-currency closes).

Taysha Gene Therapies financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$5.49M$9.77M$8.33M$15.5M$2.50M
Revenue growth—+17%-46%+518%—
Gross profit$4.34M$8.63M$7.09M$14.1M$15,000
EBITDA-$163M-$109M-$85.4M-$70.0M-$124M
Net income-$156M-$109M-$89.3M-$112M-$166M
Free cash flow-$142M-$93.8M-$81.6M-$76.9M-$109M
Capital expenditure$3.72M$738,000$374,000$7.37M$24.9M
Total debt$54.6M$70.5M$64.0M$61.1M$59.9M

Quarterly statements and history in the cockpit →

Taysha Gene Therapies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%+50%NVAXNUVBGENBTYRA0004034588688739MLYSANABAKUMSABSI688105IMCR688765TSHA6-month return →1-month return →
Up and to the right = strong over both horizons. Taysha Gene Therapies is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×250×500×750×NVAX688806NUVBGENB4588ABSIQURE688765TSHARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Taysha Gene Therapies is the large dot.

Taysha Gene Therapies competitors and peer comparison

Head to head with its named competitors (TSHA vs PTCT vs SRPT vs QURE)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Taysha Gene Therapies TSHA$1.30B-27%-13%-2,998%170.1×n/a
PTC Therapeutics PTCT$5.03B-15%-35%22%3.1×6.6%
Sarepta Therapeutics SRPT$1.56B-15%-19%0%0.9×-6.8%
uniQure QURE$1.42B-17%+28%-1,027%65.4×n/a

How Taysha Gene Therapies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Taysha Gene Therapies against its 20 peers (data as of 18 Nov 2026)
MeasureTSHAPeer medianRank in peer set
1-month return-2.9%-15.9%5th highest of 21
6-month return-27.3%-20.3%6th lowest of 20
Distance from 52-week high-45.3%-48.1%9th highest of 21
Revenue growth (TTM)-13.1%+15.8%4th lowest of 18
Operating margin-2,998.0%-38.9%2nd lowest of 19
EV / Sales170.1×8.4×4th most expensive of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%6.8×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a

Questions

Who are Taysha Gene Therapies's main competitors?
Named competitors: PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), uniQure (QURE). The cockpit's measured peer set (industry) also includes Novavax (NVAX), Zhuhai Trinomab Pharmaceutical (688806.SS), Nuvation Bio (NUVB), Generate Biomedicines (GENB), Hualan Biological Vaccine (301207.SZ), Tyra Bioscience (TYRA).
Is Taysha Gene Therapies expensive compared with its peers?
On ev / sales it trades at 170.1× against a peer median of 8.4×, 4th most expensive of 19 in its peer set.
How has Taysha Gene Therapies stock performed?
Over six months to 18 Nov 2026 the shares returned -27.3% against -20.3% for the median peer; over one year -3.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.